Develops genetic medicine candidates for people with retinal diseases and cystic fibrosis lung disease.
10-K for FY2025, filed Mar 18, 2026
Partners pay upfront and license fees, fund research and development, and reimburse expenses; milestone payments and sales royalties may also come in. License fees are earned when the license begins, while research and development services are earned over the work period.
10-K for FY2025, filed Mar 18, 2026The Company’s revenue is primarily derived through its license, research, development and commercialization agreements. The terms of these…View ↗
Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees…View ↗
The Company recognizes as revenue sales-based royalties and milestone payments at the later of (i) when the related sales occur, or (ii)…View ↗
The Company recognizes revenue when, or as, the performance obligation is satisfied. Performance obligations recognized at a point in time…View ↗
$85.2M
10-K for FY2025, filed Mar 18, 2026
$85.2M ↗
Otsuka receives licensed rights to develop and commercialize a retinal candidate in some Asia-Pacific markets; the Cystic Fibrosis Foundation funds development of a lung-disease candidate.
10-K for FY2025, filed Mar 18, 2026
No. It lost $140.1M in FY2025.
Growing. Revenue grew 4.7x in 4 years, from $18M in FY2021 to $85.2M in FY2025, about 47% a year.
Partnered commercialization rights
The older report describes the product-candidate pipeline as wholly owned; the latest describes Otsuka holding exclusive development and commercialization rights for a retinal candidate in some Asia-Pacific markets, while the company retains rights elsewhere.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 18, 2026We are developing a diverse pipeline of product candidates for both large market and rare diseases, including patient populations that…View ↗
In October 2025, we entered into a Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd. (the “Otsuka Collaboration and…View ↗
A narrower stated development focus
The older report describes candidates across eye, lung, and heart diseases; the latest centers its stated priorities on retinal disease and cystic fibrosis lung disease, with other programs advanced mainly through external funding.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 18, 2026We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials: 4D-150 for the…View ↗
We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment…View ↗
Competes with AbbVie, REGENXBIO, Adverum Biotechnologies, EyePoint, Ocular Therapeutix, Kodiak Sciences, Merck &, Regeneron Pharmaceuticals, Roche, Apellis Pharmaceuticals, Astellas Pharma, Vertex Pharmaceuticals, Sionna Therapeutics, Krystal Biotech, Arcturus Therapeutics Holdings, and Recode Therapeutics
10-K for FY2025, filed Mar 18, 2026We consider our most direct competitors in late-stage development with respect to 4D-150 for the treatment of retinal vascular diseases…View ↗
Loading...